Preoperative and adjuvant chemotherapy in non-small cell lung cancer

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.

Original languageEnglish (US)
Pages (from-to)8-12
Number of pages5
JournalSeminars in Oncology
Volume15
Issue number6 SUPPL. 7
StatePublished - 1988
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Vinca Alkaloids
Mitomycin
Combination Drug Therapy
Cisplatin
Survival Rate
Biopsy
Drug Therapy
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Preoperative and adjuvant chemotherapy in non-small cell lung cancer. / Gralla, Richard J.

In: Seminars in Oncology, Vol. 15, No. 6 SUPPL. 7, 1988, p. 8-12.

Research output: Contribution to journalArticle

@article{11c98d64cbcb47b89d9dd0d8421628bc,
title = "Preoperative and adjuvant chemotherapy in non-small cell lung cancer",
abstract = "In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.",
author = "Gralla, {Richard J.}",
year = "1988",
language = "English (US)",
volume = "15",
pages = "8--12",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 7",

}

TY - JOUR

T1 - Preoperative and adjuvant chemotherapy in non-small cell lung cancer

AU - Gralla, Richard J.

PY - 1988

Y1 - 1988

N2 - In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.

AB - In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.

UR - http://www.scopus.com/inward/record.url?scp=0024210301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024210301&partnerID=8YFLogxK

M3 - Article

C2 - 2851182

AN - SCOPUS:0024210301

VL - 15

SP - 8

EP - 12

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 7

ER -